氨基糖苷类在免疫功能低下危重患者细菌性肺炎合并感染性休克中的应用:一项前瞻性多中心多国队列的事后分析
该研究为前瞻性多中心多国队列的事后二次分析,纳入535例免疫功能低下、疑似细菌性肺炎合并脓毒症或感染性休克的成人,其中187例(35%)在另一种抗革兰阴性菌药物基础上加用氨基糖苷类。总体住院死亡率为59.6%,联合治疗组58.3% vs 未联合组60.3%(P=0.71)。校正混杂因素和中心效应后,氨基糖苷类与住院死亡率无显著关联(校正OR 1.14 [0.69-1.89]),倾向性匹配队列中结果一致(校正OR 0.89 [0.49-1.61]);与肾脏替代治疗需求也无显著关联(校正OR 0.83 [0.49-1.39],P=0.477)。在粒细胞缺乏患者和确诊细菌性肺炎患者中同样未发现显著关联。
要点
- 在免疫功能低下、疑似细菌性肺炎合并脓毒症或感染性休克的成人中,加用氨基糖苷类联合治疗与住院死亡率无显著关联(校正OR 1.14 [0.69-1.89])。
- 倾向性匹配队列中,氨基糖苷类与住院死亡率仍无显著关联(校正OR 0.89 [0.49-1.61])。
- 氨基糖苷类与肾脏替代治疗需求无显著关联(校正OR 0.83 [0.49-1.39],P=0.477)。
- 在粒细胞缺乏患者中,氨基糖苷类与结局无显著关联(校正OR 0.66 [0.23-1.85])。
- 在确诊细菌性肺炎患者中,氨基糖苷类与结局无显著关联(校正OR 1.25 [0.61-2.57])。
适用人群与场景
- 成人免疫功能低下、疑似细菌性肺炎合并脓毒症或感染性休克的患者。
研究设计与关键结果
- 研究类型为前瞻性多中心多国队列研究的事后二次分析,共纳入535例患者,其中187例(35%)在另一种抗革兰阴性菌药物基础上加用氨基糖苷类。
- 总体住院死亡率为59.6%,联合治疗组58.3% vs 未联合组60.3%(P=0.71)。
- 校正混杂因素和中心效应后,氨基糖苷类与住院死亡率无显著关联(校正OR 1.14 [0.69-1.89]);倾向性匹配队列中校正OR 0.89 [0.49-1.61]。
- 氨基糖苷类与肾脏替代治疗需求无显著关联(校正OR 0.83 [0.49-1.39],P=0.477)。
- 在粒细胞缺乏患者中,氨基糖苷类与结局无显著关联(校正OR 0.66 [0.23-1.85]);在确诊细菌性肺炎患者中校正OR 1.25 [0.61-2.57]。
证据类型、等级与局限
- 证据类型:前瞻性多中心多国队列研究的事后二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在免疫功能低下、疑似细菌性肺炎合并脓毒症或感染性休克的成人中,加用氨基糖苷类联合治疗未显示与住院死亡率或肾脏替代治疗需求的显著关联。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The routine use of empiric combination therapy with aminoglycosides during critical illness is associated with uncertain benefit and increased risk of acute kidney injury. This study aimed to assess the benefits of aminoglycosides in immunocompromised patients with suspected bacterial pneumonia and sepsis.
METHODS: Secondary analysis of a prospective multicenter study. Adult immunocompromised patients with suspected bacterial pneumonia and sepsis or septic shock were included. Primary outcome was hospital mortality. Secondary outcomes were needed for renal replacement therapy (RRT). Mortality was also assessed in neutropenic patients and in those with confirmed bacterial pneumonia. Results were further analyzed in a cohort matched on risk of receiving aminoglycosides combination.
RESULTS: Five hundred thirty-five patients were included in this analysis, of whom 187 (35%) received aminoglycosides in addition to another antibiotic effective against gram-negative bacteria. Overall hospital mortality was 59.6% (58.3% vs. 60.3% in patients receiving and not receiving combination therapy; P = 0.71). Lack of association between mortality and aminoglycosides was confirmed after adjustment for confounders and center effect (adjusted OR 1.14 [0.69-1.89]) and in a propensity matched cohort (adjusted OR = 0.89 [0.49-1.61]). No association was found between aminoglycosides and need for RRT (adjusted OR = 0.83 [0.49-1.39], P = 0.477), nor between aminoglycoside use and outcome in neutropenic patients or in patients with confirmed bacterial pneumonia (adjusted OR 0.66 [0.23-1.85] and 1.25 [0.61-2.57], respectively).
CONCLUSION: Aminoglycoside combination therapy was not associated with hospital mortality or need for renal replacement therapy in immunocompromised patients with pulmonary sepsis.
参考来源
- Lopez R, Rello J, Taccone FS, et al. Aminoglycosides in Immunocompromised Critically Ill Patients With Bacterial Pneumonia and Septic Shock: A Post-Hoc Analysis of a Prospective Multicenter Multinational Cohort. Shock. 2020. PMID: 32496415. doi:10.1097/SHK.0000000000001553
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。